TrialRMD open2024

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.